177Lu-PSMA radio-ligand therapy

被引：0
|
作者：
Chanchou, M. [1 ]
Giraudet, A. L. [2 ]
机构：
[1] UCA, Serv Med Nucl,Inserm, Ctr Jean Perrin, UMR 1240,IMoST, 58 Rue Montalembert, F-63011 Clermont Ferrand, France
[2] Ctr Leon Berard, Serv Med Nucl, Lyon, France
来源：
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 06期
关键词：
Lu-177-PSMA; RLT; PSMA-PET; MCRPC; RESISTANT PROSTATE-CANCER; TRIAL;
D O I：
10.1016/j.mednuc.2023.09.005
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Lutetium-177-labeled PSMA radio-ligand therapy is becoming more and more widespread in nuclear medicine departments, in France and around the world. Practitioners must master specificities of this treatment in order to develop this type of therapeutic care in the best conditions. This summary article presents the methods of carrying out treatment with Lu-177-PSMA in nuclear medicine departments as well as the various current clinical research subjects concerning this theme. (C) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：316 / 322
页数：7
相关论文
共 50 条
  • [31] Reply to "Fact-Checking on 177Lu-PSMA Nephrotoxicity"
    Ballal, Sanjana
    Yadav, Madhav Prasad
    Bal, Chandrasekhar
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 215 (01) : W3 - W4
  • [32] Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison
    Rinscheid, Andreas
    Dierks, Alexander
    Kircher, Malte
    Pfob, Christian
    Wengenmair, Hermann
    Wienand, Georgine
    Lapa, Constantin
    Janzen, Tilman
    Bundschuh, Ralph
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [33] 177LU-PSMA IN TREATMENT OF PROSTATE CANCER: INITIAL EXPERIENCE
    Lenzo, N.
    Meyrick, D.
    Wester, H.
    Cardaci, G.
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 15 - 15
  • [34] 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
    Assadi, Majid
    Pirayesh, Elahe
    Rekabpour, Seyed Javad
    Zohrabi, Farshad
    Jafari, Esmail
    Nabipour, Iraj
    Esmaili, Abdolhamid
    Amini, Abdullatif
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (12) : 978 - 980
  • [35] 177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer
    Perrone, Elisabetta
    Ghai, Kriti
    Eismant, Aleksandr
    Konz, Kornelia
    Baum, Richard P.
    ACTA ONCOLOGICA, 2024, 63 : 557 - 562
  • [36] Patient-specific pharmacokinetics and dosimetry over multiple therapy cycles during 177Lu-based radionuclide therapy: a study for 177Lu-DOTATATE and 177Lu-PSMA
    Gosewisch, A.
    Ermoschkin, L.
    Ilhan, H.
    Todica, A.
    Vamacka, L.
    Bartenstein, P.
    Boening, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S270 - S271
  • [37] Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer
    Hindie, Elif
    LANCET ONCOLOGY, 2021, 22 (10): : E425 - E425
  • [38] BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy
    Ahmadzadehfar, Hojjat
    Gaertner, Florian
    Lossin, Philipp S.
    Schwarz, Bettina
    Essler, Markus
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (08) : 609 - 610
  • [39] Safety and Efficacy of Extended 177Lu-PSMA Therapy: Multi-Center Retrospective Analysis
    Telli, T.
    Seifert, R.
    Lapa, C.
    Hekimsoy, T.
    Weber, W.
    Pfob, C.
    Herrmann, K.
    Rahbar, K.
    Eiber, M.
    Fendler, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S152 - S152
  • [40] DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
    Schumann, Sarah
    Scherthan, Harry
    Lapa, Constantin
    Serfling, Sebastian
    Muhtadi, Razan
    Lassmann, Michael
    Eberlein, Uta
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (08) : 1723 - 1732
12345